Incyte Corp., of Wilmington, Del., reported first-quarter GAAP net product revenue totaling $314 million for JAK inhibitor Jakafi (ruxolitinib), marking 25 percent growth over 2017. GAAP net product revenue for leukemia drug Iclusig (ponatinib) totaled $21 million vs. $14 million for the same period last year.